UBE2O Activators

The chemicals listed above are not direct activators of UBE2O but may influence its activity indirectly through their effects on the ubiquitin-proteasome system, protein stability, or related cellular pathways. UBE2O's role in ubiquitination implies its involvement in a broad array of cellular processes including protein turnover and cellular signaling. Proteasome inhibitors such as MG132, Bortezomib, and Disulfiram can impact the ubiquitin-proteasome system, potentially influencing the activity of ubiquitin-conjugating enzymes like UBE2O. By inhibiting proteasomal degradation, these compounds can affect the dynamics of protein turnover, potentially impacting the function and regulation of UBE2O.

Thalidomide and its analogs, including Lenalidomide and Pomalidomide, known as immunomodulatory imide drugs (IMiDs), modulate the ubiquitin-proteasome system. These compounds can influence the activity of E3 ligases and may indirectly affect UBE2O's unique E3 ligase function. MLN4924 (Pevonedistat) inhibits NEDD8-activating enzyme, affecting neddylation, a process related to ubiquitination. This can have downstream effects on proteins like UBE2O that are involved in ubiquitin conjugation and protein turnover. Natural compounds such as Curcumin, Resveratrol, Epigallocatechin Gallate (EGCG), Withaferin A, and Sulforaphane are known to modulate various cellular signaling pathways. These compounds can influence the cellular environment, including aspects of the ubiquitin-proteasome system, thereby potentially impacting UBE2O function.